New lipid-lowering drugs: an update
Open Access
- 16 February 2012
- journal article
- review article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 66 (3) , 270-280
Abstract
Lipid lowering is established as a proven intervention to reduce atherosclerosis and its complications. Statins form the basis of care but are not able to treat all aspects of dyslipidaemia. Many novel therapeutic compounds are being developed. These include additional therapeutics for low‐density lipoprotein cholesterol, for example, thyroid mimetics (thyroid receptor beta‐agonists), antisense oligonucleotides or microsomal transfer protein inhibitors (MTPI); triglycerides, for example, novel peroxosimal proliferator activating receptors agonists, MTPIs, diacylglycerol acyl transferase‐1 inhibitors and high‐density lipoprotein cholesterol (HDL‐C), for example, mimetic peptides; HDL delipidation strategies and cholesterol ester transfer protein inhibitors and modulators of inflammation, for example, phospholipase inhibitors. Gene therapy for specific rare disorders, for example, lipoprotein lipase deficiency using alipogene tiparvovec is also in clinical trials. Lipid‐lowering drugs are likely to prove a fast‐developing area for novel treatments as possible synergies exist between new and established compounds for the treatment of atherosclerosis.Keywords
This publication has 109 references indexed in Scilit:
- Effect of Two Intensive Statin Regimens on Progression of Coronary DiseaseNew England Journal of Medicine, 2011
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL CholesterolJAMA, 2011
- ApoB siRNA‐induced Liver Steatosis is Resistant to Clearance by the Loss of Fatty Acid Transport Protein 5 (Fatp5)Lipids, 2011
- GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing EffectsCell, 2010
- Biological, clinical and population relevance of 95 loci for blood lipidsNature, 2010
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysisThe Lancet, 2010
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009
- Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptorBiochemical Journal, 2009
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006